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Introduction: Biofutures/Biopresents
KEAN BIRCH
University of Glasgow, Glasgow, UK
The UK bioscience industry faces an exciting future. The technology offers new
medical opportunities that challenge traditional patterns of diagnosis, healthcare
and disease prevention. The UK, with a reformed National Health Service, has an
opportunity to be at the forefront of research and development [Prime Minister
Blair, foreword in BIGT (2003, p. 1). My emphasis].
Introduction
Two very different reports produced for the UK government in the last three years have
connected the state of our physical health with that of our material wealth. The first of
these was produced in 2003 by the Bioscience Innovation and Growth Team (BIGT)
titled Improving National Health, Improving National Wealth, whilst the second, called
Health Inequalities—Status Report on the Programme for Action, was produced in 2005
by the Department of Health (DH).1 The former produced a series of recommendations
designed to ‘secure’ the economic position of the UK bioscience industry and through
this the health of the UK population, whilst the latter repeated the finding that socio-econ-
omic status and physical health are strongly related, revealing significant spatial and social
health inequalities across the UK (see Batty, 2005; Shaw et al., 2005).
These different understandings of the health–wealth link provide a useful foil to explore
the central focus of this special issue, namely the construction and definition of particular
problems and their solutions encompassing the technoscience of new genetics. Here the
popular term technoscience is used to denote a technological context that promotes and
maintains forms of scientific enquiry and understanding particular to that set of artefacts:
in its simplest formulation, it posits that technology is both shaped by and shapes society.
In this special issue we seek to explore the specific technoscientific context in which the
biosciences—molecular biology, genetics, genomics, proteomics—are situated and
subsequently promulgated: their biopresents and their biofutures.
Using the government reports above to illustrate the context of the biosciences reveals two
very different approaches to understanding national healthcare. The BIGT report implies
that our health is dependent upon ensuring future industrial performance through building ‘a
mutually advantageous collaboration between the NHS and industry for patient benefit’
(2003, p. 5). In contrast, the DH report implies that our health is dependent upon existing
resource distribution with the government response, according to Shaw et al. (2005), con-
sisting of an ‘individualistic rhetoric of behavioural prevention [of illness]’ as opposed to
building ‘mutually advantageous’ alliances between different institutions. This is exempli-
fied in the DH proposal for ‘health trainers’ for deprived areas which Caroline Flint MP,
Minister for Public Health, says would assist people in adopting ‘a healthier way of life’
(quoted in Batty, 2005). Other wide-ranging changes to the UK health service have also
been oriented towards promoting such an agenda based on personal choice, healthier life-
styles and medical innovations derived from modern biotechnology (i.e. targeted at individ-
uals). Furthermore, this agenda has been supported by the extension of privatized provision
of services across the NHS [see Pollock (2004) for a critical review].
What are the social and technological consequences of such policies? These issues have
a longstanding tradition in social studies of ‘new genetics’ with the work by Abby
Lippman (1992, p. 1473) on ‘geneticization’ illustrating the early concern that ‘[t]he indi-
vidual, not society, is seen to require change’ and therefore ‘social problems improperly
become individual pathologies’. This focus on individual responsibility for health
means that as our bodies—both literal and public—in the biopresent are increasingly
privatized, reduced to their medicalized and essentialized component parts (i.e. ‘the
gene’), then the biofuture responses—both private and public—to our bodies will also pro-
gressively privatize and medicalize our bodies thereby reinforcing the original individual-
ist perspective (Cunningham-Burley and Boulton, 2000; Gottweis, 2005).
Linking Biofutures and Biopresents
These biofuture agendas and their technoscientific remedies are presented as the obvious
solution to the constructed and naturalized problem of the biopresent. The range of possible
biofutures reveals the contextual diversity in which the linkages between biofutures and
biopresents occur, a diversity that is eroded as technoscientific promises and solutions
marginalize some accounts of the world in favour of others. Thus the biopresent discussed
above, concerning the relationship between health and wealth, privileges a biofuture in
which the understanding of human well-being is based on the individual characteristics
and behaviour of each physical body. The material expense incurred as a consequence
of individualized responses escalates the overall cost to society accordingly, foreclosing
the adoption of other possibilities or concerns (Rappert and Brown, 2000; Duster, 2003).
For example, healthcare technologies derived from the biosciences produce the means
to screen populations and test individuals before treatment by gene-based technologies
(i.e. pharmacogenetics), where these exist. However, the integration of such technologies
into treatments is strongly influenced by the subsequent increase in costs to businesses of
clinical trials and the impact this will have on their priorities (Webster et al., 2004). The
main question to consider then is how do we identify possible biopresents and biofutures?
And once we have, how do we understand their technoscientific extension?
Agendas and Artefacts
As particular technological visions of the future, these biofutures promote a self-fulfilling
prophecy. The promotion of certain agendas is confirmed as rational and coherent because
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a specific biofuture is promoted in scenarios, policy and practice whilst others are not.
In relation to medicine for example, individualized prevention and treatment is based
on conceptions of humanity drawn from genetics, genomics and other biosciences that
breaks down our bodies into component parts (i.e. genes, genomes, cells). The agendas
of scientists, companies, universities and patients all benefit from this research
direction, with scientists working in these fields richly rewarded for their efforts, both
materially (i.e. stock options) and socially (i.e. status). In turn, public and private
organizations have been rewarded through changes to intellectual property institutions
(e.g. Bayh–Dole Act, 1980) that have reinforced an individualistic and proprietary
understanding of invention that assures the legitimacy of their private appropriation of
valuable intellectual property (see McAfee, 2003). Finally, patient groups have been
rewarded, where they have achieved public awareness, with research investment in
their particular disease or disorder, motivating other groups to pursue similar strategies
(Rose, 2001).
As these agendas coalesce into biofutures, they become embedded in technologies and
artefacts which confirm the self-fulfilling agendas: they both construct and naturalize the
specific biofutures as obvious/inevitable. For example, Rappert and Brown (2000, p. 52)
argue that ‘[s]tatements about the future of genetic diagnostics often present its develop-
ment with a certain quality of inevitability’. This apparent inevitability is produced by
embedding agendas in artefacts, yet still appearing as freely adopted by pre-empting
alternatives. In modern biomedicine, the technologies and artefacts of genetic screening
help to produce a perception that there are ‘undesirable’ characteristics that individuals
need to be screened for and then correct (Duster, 2003), whether or not there is any
means to do so (see Caulfield, 2000).
Solutions and Remedies
Implicit within the biofuture agendas and their embedding in artefacts is the construction
and naturalization of the biopresent as a problem. A biopresent is the current state of
affairs as conceived by the set of agendas that then produces the biofuture; it enables
the enrolment of these agendas into the biofuture because it portrays the technological sol-
utions as obvious. In medicine one of the most powerful biopresents is disease: it can be
constructed via campaigns that medicalize and therefore naturalize specific characteristics
(e.g. baldness) or behavioural traits (e.g. shyness) as problems for individuals (Moynihan,
2002; Moynihan and Cassels, 2005). The construction of problematic traits or character-
istics, and their subsequent medicalization, is pursued where such ‘problems’ are non-
fatal, helping to produce a large commercial target of ‘worried well’ (Angell and
Relman, 2002) or lifestyle consumers (Moynihan and Cassels, 2005). Thus a new
disease market for an existing product can be more profitable than the creation of a new
product. This advantage partly explains why the bioscience ‘revolution’ has not led to a
flood of new, more effective treatments (Arundel and Mintzes, 2004; Nightingale and
Martin, 2004; Joppi et al., 2005; Mittra, 2005).2
The biofuture agendas and their technoscientific remedies are presented as the
obvious solution to the constructed and naturalized problem of the biopresent. To do
so the biofuture and its technoscientific remedy must be constituted in a specific
way that not only reflects on the problem implicit within the biopresent, but also the
inevitability and obviousness of the biofuture’s solution. A biopresent that constructs
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certain diseases and disorders as major problems to be solved by specific technological
treatments, results in a biofuture that justifies its solutions as revolutionary in order to
legitimate the expenditure of resources (public and private) on specific activities and
enrol multiple agendas (Va¨liverronen, 2004). Such claims, visions and expectations
are an integral part of technoscientific development (Hedgecoe and Martin, 2003).
All such representations exist as an aspect of technology and no technology can
exist without these representations. As Usher Fleising (2001, p. 240) argues, ‘geno-
hype’ becomes ‘an ideology where disease is defined as a market opportunity’ (see
also Caulfield, 2000).
Technoscientific Expectations
There has been a growing interest recently in what has come to be known as the ‘sociology
of technological expectations’, which emphasizes the important role played by such rep-
resentations—visions, promises and even ethical discourses—to the development of tech-
nologies (van Lente and Rip, 1998; Brown et al., 2000; Brown and Michael, 2003;
Hedgecoe and Martin, 2003). These act to enrol a range of disparate actors, possibly
with competing agendas, and material resources into a technoscientific system; for
example, Hedgecoe and Martin (2003) have explored the importance of bioethical dis-
courses, in particular, to the development of pharmacogenetics. A crucial aspect of this
use of visions, promises and other expectations, especially in relation to the positing of
a revolution in the biosciences, is the enrolment of material resources in the form of invest-
ment (Walsh, 2002). As a consequence, these representations come to form ‘social insti-
tutions as well as patterns of activity’ that are deliberately endorsed in an attempt to induce
a self-fulfilling prophecy around a specific technoscientific discourse (Guice, 1999,
pp. 81–82; see also Brown et al., 2000).
Although the pursuit and promotion of these expectations is future-oriented, Brown and
Michael (2003) argue that there is an important past-oriented aspect as well. The former
they characterize as a ‘fetishization of the soon to be’, whilst the latter they argue results
from:
an overwhelming tendency retrospectively to account for success or failure by referring
to the properties of a technology or an artefact rather than other equally important
[i.e. social, economic, political] factors (Brown and Michael, 2003, pp. 6, 7).
The interpretation of the past therefore appears as another temporal orientation within
technoscientific development (see Rappert, 1999); all of which point to a series of legit-
imating and justificatory claims that are derived from temporal periods lying outside of
the current development stage. It can therefore be argued that the positioning of the bio-
sciences as a revolutionary technoscientific development reinforces the impression that
specific technoscientific outcomes are either inevitable or inherent, producing a techno-
logically determinist position, which Brown and Michael (2003) suggest can cause the
failure of the very technologically determined future expected because such determinism
leads to the neglect of social, economic and political aspects of development. On the other
hand, it is possible to argue that such an emphasis on social factors as an explanation of
technoscience can, through the creation of self-fulfilling prophecies, naturalize these
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social, economic and political features of technologies as the cause of their uptake and dif-
fusion. These concerns represent the focus of the articles in this special issue.
Special Issue
In his article, Adam Bostanci compares two sets of agendas and the respective artefacts
that these generate as a result of the essentialistic perspectives reproduced during the
‘contest’ between the Human Genome Project (HGP) and Celera Genomics to map the
human genome. The agendas of each project are reflected in the creation of the two
genome artefacts that then illustrate an overriding question: what is the human
genome? How has each sequence been represented? Bostanci presents these issues in
light of the role played by human diversity as an underlying essentialist notion used to
legitimate and thereby encourage support for both projects. For example, despite the
admission that the choice of DNA donor for genome sequencing was an arbitrary decision,
both projects sought to ensure that racial and gender diversity was both part of the
sequenced genome itself and its representation afterwards.
Michal Nahman’s article deals with the contradictory meanings attached to ideas of
purity and contamination that are produced in the characterization of egg donation off-
spring in Israel as ‘a different mixture’. She argues that this represents a materialization
of national identity and personhood specific to Israel, particularly the idea of ‘blending
the exiles’, with the perception that egg donor offspring are ‘more’ than their parents.
Such a perception is derived from the ‘chosenness’ of the offspring, which in turn
carries over into the artefacts used to identify donor candidates by the parents in the
donor clinics. Thus Nahman shows how the choices Israeli parents make—in reference
to the ‘preferred external features’ of the donor—are tied to a concept of a global
society where the personal qualities of the egg donor become central concerns.
Consequently Israeli parents appear ‘obsessed’ with choosing egg donors with small
noses and white skin, thereby materializing their national identity in relation to specific
geographical preferences; i.e. white European.
Caitriona McLeish discusses the response of the US scientific community to the
perceived dual-use threat from bio-weapons after the 2001 terror attack on the USA. In
her analysis of their response, McLeish shows how a set of agendas came to frame the
expected threat, driving the adoption of self-censorship policies by journal editors. She
deals with three different proposals to limit the publication of dual-use information, start-
ing with the 2003 statement by 32 journal editors and authors that outlined dissemination
procedures for restricting publication. This McLeish follows with the 2004 Fink Commit-
tee Report and the 2005 decision by the Proceedings of the National Academy of Science
to embargo an article. Throughout this discussion she explores the framing of the threat
issue by the different actors involved, particularly the scientific and weapons control
communities.
In their article on biobanks Helen Busby and Paul Martin highlight the use of pleas to
altruism based on national identity as a means to enrol national populations in genetic
research. Donors to biobanks gain no personal advantage—in terms of better
treatment—so they can have no individualized motivation to cooperate. As Busby and
Martin argue, donor support instead depends upon appeals to a national identity, exempli-
fied by Benedict Anderson’s concept of the ‘imagined community’. Thus to support
Biobank UK proponents have had to stress the progressive benefits to the national
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population, future inhabitants and communities, where these are framed in terms of
national groups that are themselves constructed as homogeneous (i.e. Iceland) or hetero-
geneous (i.e. UK). Both have been presented as potential benefits to medical research that
utilizes the biobank. Consequently, the National Health Service (NHS) has been recast as a
biomedical research tool that contributes to the ongoing agendas of industrial innovation
in the biosciences (despite public disquiet about such an emphasis) and, therefore, to
national economic interests.
Finally, Michael Hopkins focuses on the ‘hidden research system’ of cytogenetic testing
in the NHS that evolved from a reconfiguration of existing artefacts through experimental
practice. He provides a detailed history of the cytogenetic agendas throughout the twen-
tieth century that arose as diseases came to be associated with chromosomal abnormalities.
In turn the coupling of cytogenetics with amniocentesis facilitated the expansion of tech-
niques into prenatal testing and the growth of a particular community of practice (i.e. the
Clinical Genetics Society) centred on the new service provided from this technoscience. In
this case, it appears as though the various agendas arose from the reconfiguration of arte-
facts and the development of techniques in response to new influences on the network (i.e.
reducing the length of waiting times for results).
Social Science Roles and Responsibility
So what do these biofutures and biopresents mean for the work of social scientists? There
is at least one crucial way that the social sciences, as well as the social world more gen-
erally, are affected by the production of biofutures and biopresents—that is in relation to
resource allocation, both in terms of research focus and material expenditure. Such a
concern is especially relevant for social scientists now in several jurisdictions including
the UK, USA and EU amongst others. A growth of social science research interest in
the ‘biosciences’ is evident over the last few decades, especially since 2000, as a search
of the BIDS International Bibliography of the Social Sciences shows.3 The increasing
level of material expenditure on bioscience research can be illustrated in reference to
the concerted UK investment in social research on ‘genomics’ over the past few years;
for example, the Economic and Social Research Council (ESRC) alone is spending
£12.5 million over 10 years (Diamond and Woodgate, 2005). The proliferation of research
centres and programmes across a number of countries focused on the various aspects of
‘new genetics’ represents a strong commitment to a particular technoscientific field that
may not prove to fulfil its potential for solutions to a multitude of social problems as
touted by its advocates. What happens to the other research agendas, ones that concentrate
on other ways of understanding the world?
Why does this matter? And what does it all mean? The work of Ferraro et al. (2005)
provides an important analysis of this very issue, although in relation to economic
thought rather than the biosciences. They argue that social scientists are subject to what
Anthony Giddens calls the ‘double hermeneutic’ in that when we describe the world we
inevitably modify it through our theories because they prescribe particular approaches
to understanding the world that encourage and endorse particular policies and decisions.
Thus we contribute to a self-fulfilling prophecy in which the prescribed policies and
decisions reinforce the original theory by ‘proving’ its accuracy. If we report on the bio-
sciences in terms that corroborate the expectations of individualized lives and privatized
bodies, then our descriptions can promote a particular socio-economic system (i.e. private
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appropriation) that reproduces certain cultural expectations (i.e. individualism). We have
to ask whether we wish our own research to promote these agendas and, if not, how do we
avoid doing so.
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Notes
1The DH release strategy for the report was strongly criticized by Shaw et al. (2005) in a British Medical
Journal (BMJ) editorial. They charged that the current government’s release strategy was an almost direct
replication of the previous Conservative administration’s response to two previous reports detailing the
link between health inequalities and socio-economic inequalities: the 1980 Black Report and 1987
Health Divide. This claim was refuted by the Minister for Public Health, Caroline Flint in a response to
the BMJ piece (Flint, 2005).
2David Rasnick (2003, p. 356) has been particularly scathing in his analysis of the ‘biotechnology bubble
machine’ arguing that most biopharmaceutical products are ‘for rare diseases with small markets’ or ‘plain
don’t work’.
3The clearest indication of this growth can be shown from a simple search of BIDS International Bibli-
ography of the Social Sciences. Such a search reveals that for the 1980s there was an annual average of
just over 27 articles concerning a ‘genetic’ topic: a figure that has subsequently increased to nearly 62
for the 1990s and 245 for the first half of the 2000s. A similar level of increase is also evident in relation
to both ‘biology’ and ‘biotechnology’ topics, as shown in Table A1 in the Appendix. The search shows that
the interest in genetics should, on current trends, by the end of the decade have increased eight-fold from
the 1990s.
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Appendix
Table A1. Average annual number of articles with reference to the ‘biosciences’ per
decade
Search word 1970–1979 1980–1989 1990–1999 2000–2004
‘Genetic’ 17.7 27.4 61.9 245
‘Biology’ 18 36.9 134.1 338
‘Biotechnology’ 0 7.5 62.8 137.2
‘Stem cell’ 0 0 0 5
Source: BIDS International Bibliography of the Social Sciences, June 2005.
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